GLP-1s for Addiction: Early Signals, Still Many Questions
Glucagon-like peptide-1 receptor agonists, originally used for diabetes and obesity, are being explored as addiction treatments. Early data from animal studies, observational research, and some randomized trials suggest GLP-1s may dampen reward-driven cravings and reduce alcohol consumption, with semaglutide showing reductions in craving and heavy drinking in alcohol use disorder; results for opioid, cocaine, and nicotine use disorders are less robust and mostly preclinical. The drugs likely act on shared brain reward pathways and may broadly decrease reward seeking, not just addiction-specific cravings. Many critical questions remain about which patients benefit, optimal dosing and duration, durability after stopping, interactions with comorbidities, and equitable access. Large, longer-term trials are ongoing, and GLP-1s are not yet ready to replace established addiction treatments.
